Given that anandamide also activates GPR55 and CB2, it is possible that genetic deletion of FAAH leads to anandamide acting not only on CB1, but instead on the endocannabinoid system as a whole, to improve cognitive function and attenuate the onset of markers of AD. The gene discussed is FAAH; the disease is Alzheimer disease.